Cosmos & Physics
Revolution Medicines Reports Promising Pancreatic Cancer Drug Results
Patients with previously treated metastatic pancreatic cancer lived an average of 13 additional months with Revolution Medicines' new drug, daraxonrasib, more than double the survival rate of standard
Dr. Evelyn Reed·May 31, 2026
